Across TCGA pan-cancer cohorts, FCER1A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FCER1A data layer compared with 24 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FCER1A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FCER1A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
LSCC and LUAD are the cancer types where FCER1A mass-spec protein most reproducibly stratifies survival.